Business
Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just as regulatory and government policies spark momentum and frustration.
FEATURED STORIES
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Immunai today announced it has received $60 million in Series A funding, bringing its total funding since inception in December 2018 to $80 million.
AbbVie committed up to another $300 in potential milestone payments.
There have been a few life sciences companies that have been attracting attention this week with strong Series A rounds.
The choice for the new FDA commissioner will tell the public about the Biden administration’s battle plan with regards to handling the global pandemic.
BigHat is a Bay-area startup that’s reimagining antibody development with the help of AI and ML (machine learning) technologies through data-driven discovery.
ZYESAMI is intended to block the replication of SARS-CoV-2 in the ATII cell, as well as cytokine synthesis, thereby relieving respiratory distress. It is the only treatment in development that targets these ATII cells, and if approved, would be the first drug on the market for COVID-19 patients critically ill with respiratory failure.
Anat Ashkenazi was tapped to take over as chief financial officer of Eli Lilly following the abrupt resignation of Josh Smiley, who departed the company following allegations of an inappropriate relationship with an employee.
Here’s a recap of companies announcing facility expansions this past month and life sciences job creations across the nation.
He will be replaced on an interim-basis by Thomas McCourt, who currently serves as company president.